Effect of fluoxetinein treatment of vitiligo

Investigating the effect of adding oral fluoxetine to topical corticosteroid treatment in patients with limited vitiligo form

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221020056251N1

Enrollment

Registered

2023-02-28

Start date

2023-02-04

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: Clobetazol ointment is used daily for 3 hours and Fluoxetine 20 tablets are used daily for 3 months. The training class on how to take the drugs is given once for e

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Have not received any topical treatment or phototherapy during the past month. Lack of follicle pigmentation Absence of white hair in loss Their lesions should be on the limbs and trunk, except for the ends of the limbs and genitalia and around the nails and folds The extent of involvement is less than 20% of the total body surface. No history of any psychiatric disorder No simultaneous use with monoamine oxidase inhibitor drugs (MAOI) No history of hypersensitivity reaction to Fluoxetine or any of the compounds in the formulation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The size of the lesion. Timepoint: 3 months after starting treatment. Method of measurement: The surface area of the lesion.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr nazila poostiyan

Esfahan University of Medical Sciences

n.poostiyan@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026